Friday, March 25, 2022 5:23:30 PM
It really isn't...
This disclosure issue is a matter of both shareholder/future investor trust, and of mandatory disclosure. They stated unequivocally that they are making a cash purchase, but don't say how much, don't fully verify that the deal is closed, there are no new issuances, and their books don't reflect any new assets, new debt, or new revenue. Did the deal actually happen (we haven't seen a termination of a material agreement PR either)? Is it still pending? Will this impact the company in some material way (new debt, new assets, new revenue, new stock issuance) down the road?
Honestly, I don't care what the net result is - good, bad, or indifferent.
But as a shareholder, I have a right (and the company has an obligation) to disclose it...the uncertainty that they keep perpetuating is making it difficult for new investors to come into the fold, which keeps is stuck in sub penny land. If Barron & Co. can't handle these basic aspects of running a public company, they need to find management who can. Even in pink land, this is basic stuff.
This disclosure issue is a matter of both shareholder/future investor trust, and of mandatory disclosure. They stated unequivocally that they are making a cash purchase, but don't say how much, don't fully verify that the deal is closed, there are no new issuances, and their books don't reflect any new assets, new debt, or new revenue. Did the deal actually happen (we haven't seen a termination of a material agreement PR either)? Is it still pending? Will this impact the company in some material way (new debt, new assets, new revenue, new stock issuance) down the road?
Honestly, I don't care what the net result is - good, bad, or indifferent.
But as a shareholder, I have a right (and the company has an obligation) to disclose it...the uncertainty that they keep perpetuating is making it difficult for new investors to come into the fold, which keeps is stuck in sub penny land. If Barron & Co. can't handle these basic aspects of running a public company, they need to find management who can. Even in pink land, this is basic stuff.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
